<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 05 Sep 2024 20:11:01 +0000</lastbuilddate>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Transfemoral or surgical aortic valve replacement in young low-risk patients with tricuspid and bicuspid aortic valve stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39235157/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 5:ehae537. doi: 10.1093/eurheartj/ehae537. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39235157/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39235157</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae537>10.1093/eurheartj/ehae537</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39235157</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Niklas Schofer</dc:creator>
<dc:creator>Stefan Blankenberg</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transfemoral or surgical aortic valve replacement in young low-risk patients with tricuspid and bicuspid aortic valve stenosis</dc:title>
<dc:identifier>pmid:39235157</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae537</dc:identifier>
</item>
<item>
<title>Macrophage-Expressed Coagulation Factor 7 Promotes Adverse Cardiac Remodeling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39234697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Extravascular TF-F7-PAR2 complex signaling drives inflammatory macrophage polarization in ischemic heart disease. Targeting this signaling complex for specific therapeutic macrophage reprogramming following MI attenuates cardiac fibrosis and improves cardiovascular function.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 5. doi: 10.1161/CIRCRESAHA.123.324114. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Excess fibrotic remodeling causes cardiac dysfunction in ischemic heart disease, driven by MAP (mitogen-activated protein) kinase-dependent TGF-ß1 (transforming growth factor-ß1) activation by coagulation signaling of myeloid cells. How coagulation-inflammatory circuits can be specifically targeted to achieve beneficial macrophage reprogramming after myocardial infarction (MI) is not completely understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Mice with permanent ligation of the left anterior descending artery were used to model nonreperfused MI and analyzed by single-cell RNA sequencing, protein expression changes, confocal microscopy, and longitudinal monitoring of recovery. We probed the role of the tissue factor (TF)-factor 7 (F7)-integrin ß1-PAR2 (protease-activated receptor 2) signaling complex by utilizing genetic mouse models and pharmacological intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Cleavage-insensitive PAR2<sup>R38E</sup> and myeloid cell integrin ß1-deficient mice had improved cardiac function after MI compared with controls. Proximity ligation assays of monocytic cells demonstrated that colocalization of F7 with integrin ß1 was diminished in monocyte/macrophage F7-deficient mice after MI. Compared with controls, F7<sup>fl/fl</sup> CX3CR1<sup>Cre</sup> mice showed reduced TGF-ß1 and MAP kinase activation, as well as cardiac dysfunction after MI, despite unaltered overall recruitment of myeloid cells. Single-cell mRNA sequencing of CD45 (cluster of differentiation 45)<sup>+</sup> cells 3 and 7 days after MI uncovered a trajectory from recruited monocytes to inflammatory TF<sup>+</sup>/F7<sup>+</sup>/TREM (triggered receptor expressed on myeloid cells) 1<sup>+</sup> macrophages. As early as 7 days after MI, macrophage F7 deletion led to an expansion of reparative Olfml (olfactomedin) 3<sup>+</sup> macrophages and, conversely, to a reduction of TF<sup>+</sup>/F7<sup>+</sup>/TREM1<sup>+</sup> macrophages, which were also reduced in PAR2<sup>R38E</sup> mice. Short-term treatment from days 1 to 5 after nonreperfused MI with a monoclonal antibody inhibiting the macrophage TF-F7-PAR2 signaling complex without anticoagulant activity improved cardiac dysfunction, decreased excess fibrosis, attenuated vascular endothelial dysfunction, and increased survival 28 days after MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Extravascular TF-F7-PAR2 complex signaling drives inflammatory macrophage polarization in ischemic heart disease. Targeting this signaling complex for specific therapeutic macrophage reprogramming following MI attenuates cardiac fibrosis and improves cardiovascular function.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39234697/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39234697</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324114>10.1161/CIRCRESAHA.123.324114</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39234697</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Venkata Garlapati</dc:creator>
<dc:creator>Qi Luo</dc:creator>
<dc:creator>Jens Posma</dc:creator>
<dc:creator>Melania Aluia</dc:creator>
<dc:creator>Than Son Nguyen</dc:creator>
<dc:creator>Kristin Grunz</dc:creator>
<dc:creator>Michael Molitor</dc:creator>
<dc:creator>Stefanie Finger</dc:creator>
<dc:creator>Gregory Harms</dc:creator>
<dc:creator>Tobias Bopp</dc:creator>
<dc:creator>Wolfram Ruf</dc:creator>
<dc:creator>Philip Wenzel</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Macrophage-Expressed Coagulation Factor 7 Promotes Adverse Cardiac Remodeling</dc:title>
<dc:identifier>pmid:39234697</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324114</dc:identifier>
</item>
<item>
<title>EPAS1 Attenuates Atherosclerosis Initiation at Disturbed Flow Sites Through Endothelial Fatty Acid Uptake</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39234692/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Endothelial EPAS1 attenuates atherosclerosis at sites of disturbed flow by maintaining EC proliferation via fatty acid uptake and metabolism. This endothelial repair pathway is inhibited in obesity, suggesting a novel triglyceride-PHD2 modulation pathway suppressing EPAS1 expression. These findings have implications for therapeutic strategies addressing vascular dysfunction in obesity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 5. doi: 10.1161/CIRCRESAHA.123.324054. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atherosclerotic plaques form unevenly due to disturbed blood flow, causing localized endothelial cell (EC) dysfunction. Obesity exacerbates this process, but the underlying molecular mechanisms are unclear. The transcription factor EPAS1 (HIF2A) has regulatory roles in endothelium, but its involvement in atherosclerosis remains unexplored. This study investigates the potential interplay between EPAS1, obesity, and atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Responses to shear stress were analyzed using cultured porcine aortic EC exposed to flow in vitro coupled with metabolic and molecular analyses and by en face immunostaining of murine aortic EC exposed to disturbed flow in vivo. Obesity and dyslipidemia were induced in mice via exposure to a high-fat diet or through Leptin gene deletion. The role of <i>Epas1</i> in atherosclerosis was evaluated by inducible endothelial <i>Epas1</i> deletion, followed by hypercholesterolemia induction (adeno-associated virus-PCSK9 [proprotein convertase subtilisin/kexin type 9]; high-fat diet).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: En face staining revealed EPAS1 enrichment at sites of disturbed blood flow that are prone to atherosclerosis initiation. Obese mice exhibited substantial reduction in endothelial EPAS1 expression. Sulforaphane, a compound with known atheroprotective effects, restored EPAS1 expression and concurrently reduced plasma triglyceride levels in obese mice. Consistently, triglyceride derivatives (free fatty acids) suppressed EPAS1 in cultured EC by upregulating the negative regulator PHD2. Clinical observations revealed that reduced serum EPAS1 correlated with increased endothelial PHD2 and PHD3 in obese individuals. Functionally, endothelial EPAS1 deletion increased lesion formation in hypercholesterolemic mice, indicating an atheroprotective function. Mechanistic insights revealed that EPAS1 protects arteries by maintaining endothelial proliferation by positively regulating the expression of the fatty acid-handling molecules CD36 and LIPG to increase fatty acid beta-oxidation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Endothelial EPAS1 attenuates atherosclerosis at sites of disturbed flow by maintaining EC proliferation via fatty acid uptake and metabolism. This endothelial repair pathway is inhibited in obesity, suggesting a novel triglyceride-PHD2 modulation pathway suppressing EPAS1 expression. These findings have implications for therapeutic strategies addressing vascular dysfunction in obesity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39234692/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39234692</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324054>10.1161/CIRCRESAHA.123.324054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39234692</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pirri</dc:creator>
<dc:creator>Siyu Tian</dc:creator>
<dc:creator>Blanca Tardajos-Ayllon</dc:creator>
<dc:creator>Sophie Irving</dc:creator>
<dc:creator>Francesco Donati</dc:creator>
<dc:creator>Scott P Allen</dc:creator>
<dc:creator>Tadanori Mammoto</dc:creator>
<dc:creator>Gemma Vilahur</dc:creator>
<dc:creator>Lida Kabir</dc:creator>
<dc:creator>Jane Bennett</dc:creator>
<dc:creator>Yasmin Rasool</dc:creator>
<dc:creator>Charis Pericleous</dc:creator>
<dc:creator>Guianfranco Mazzei</dc:creator>
<dc:creator>Liam McAllan</dc:creator>
<dc:creator>William R Scott</dc:creator>
<dc:creator>Thomas Koestler</dc:creator>
<dc:creator>Urs Zingg</dc:creator>
<dc:creator>Graeme Birdsey</dc:creator>
<dc:creator>Clint Miller</dc:creator>
<dc:creator>Torsten Schenkel</dc:creator>
<dc:creator>Emily V Chambers</dc:creator>
<dc:creator>Mark Dunning</dc:creator>
<dc:creator>Jovana Serbanovic-Canic</dc:creator>
<dc:creator>Francesco Botrè</dc:creator>
<dc:creator>Akiko Mammoto</dc:creator>
<dc:creator>Suowen Xu</dc:creator>
<dc:creator>Elena Osto</dc:creator>
<dc:creator>Weiping Han</dc:creator>
<dc:creator>Maria Fragiadaki</dc:creator>
<dc:creator>Paul C Evans</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>EPAS1 Attenuates Atherosclerosis Initiation at Disturbed Flow Sites Through Endothelial Fatty Acid Uptake</dc:title>
<dc:identifier>pmid:39234692</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324054</dc:identifier>
</item>
<item>
<title>Disparities in Emergency Medical Services Use, Prehospital Notification, and Symptom Onset to Arrival in Patients With Acute Stroke</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39234678/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this national cross-sectional study, Black race was associated with prolonged onset to time of arrival intervals and significantly decreased odds of EMS prehospital notification, despite similar use of EMS transport. Greater county-level deprivation was also associated with reduced odds of EMS prehospital notification and slightly prolonged stroke symptom onset to emergency department arrival time. Efforts to reduce place-based disparities in stroke care must address significant...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 5. doi: 10.1161/CIRCULATIONAHA.124.070694. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Disparities in time to hospital presentation and prehospital stroke care may be important drivers in inequities in acute stroke treatment rates, functional outcomes, and mortality. It is unknown how patient-level factors, such as race and ethnicity and county-level socioeconomic status, affect these aspects of prehospital stroke care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Cross-sectional study of patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage in the Get With the Guidelines-Stroke registry, presenting from July 2015 to December 2019, with symptom onset &lt;24 hours. Multivariable logistic regression and quantile regression were used to investigate the outcomes of interest: emergency medical services (EMS) transport (versus private vehicle), EMS prehospital notification (versus no prehospital notification), and stroke symptom onset to time of arrival at the emergency department. Prespecified covariates included patient-level, hospital-level, and county-level characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The inclusion criteria was met by the 606 369 patients. Of the patients, 51.2% were men and 69.9% White, with a median National Institutes of Health Stroke Severity of 4 (IQR, 2-10), and median social deprivation index (SDI) of 51 (IQR, 27-75). Median symptom onset to arrival time was 176 minutes (IQR, 64-565). Black race was significantly associated with prolonged symptom onset to emergency department arrival time (+28.21 minutes [95% CI, 25.59-30.84]), and decreased odds of EMS prehospital notification (OR, 0.80 [95% CI, 0.78-0.82]). SDI was not associated with differences in EMS use but was associated with lower odds of EMS prehospital notification (upper SDI tercile versus lowest, OR, 0.79 [95% CI, 0.78-0.81]). SDI was also significantly associated with stroke symptom onset to emergency department arrival time (upper SDI tercile versus lowest +2.56 minutes [95% CI, 0.58-4.53]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this national cross-sectional study, Black race was associated with prolonged onset to time of arrival intervals and significantly decreased odds of EMS prehospital notification, despite similar use of EMS transport. Greater county-level deprivation was also associated with reduced odds of EMS prehospital notification and slightly prolonged stroke symptom onset to emergency department arrival time. Efforts to reduce place-based disparities in stroke care must address significant inequities in prehospital care of acute stroke and continue to address health inequities associated with race and ethnicity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39234678/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39234678</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070694>10.1161/CIRCULATIONAHA.124.070694</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39234678</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Regina Royan</dc:creator>
<dc:creator>Brian Stamm</dc:creator>
<dc:creator>Timmy Lin</dc:creator>
<dc:creator>Janette Baird</dc:creator>
<dc:creator>Christopher Becker</dc:creator>
<dc:creator>Rebecca Karb</dc:creator>
<dc:creator>Tina Burton</dc:creator>
<dc:creator>Dawn Kleindorfer</dc:creator>
<dc:creator>Shyam Prabhakaran</dc:creator>
<dc:creator>Tracy E Madsen</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Disparities in Emergency Medical Services Use, Prehospital Notification, and Symptom Onset to Arrival in Patients With Acute Stroke</dc:title>
<dc:identifier>pmid:39234678</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070694</dc:identifier>
</item>
<item>
<title>Experimental TET2 Clonal Hematopoiesis Predisposes to Renal Hypertension Through an Inflammasome-Mediated Mechanism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39234670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Tet2-mediated CH sensitizes mice to a hypertensive stimulus. Mechanistically, the expansion of hematopoietic Tet2-deficient cells promotes hypertension due to elevated renal immune cell infiltration and activation of the NLRP3 inflammasome, with consequences on sodium retention. These data indicate that carriers of TET2 CH could be at elevated risk for the development of hypertension and that immune modulators could be useful in treating hypertension in this patient population.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 5. doi: 10.1161/CIRCRESAHA.124.324492. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertension incidence increases with age and represents one of the most prevalent risk factors for cardiovascular disease. Clonal events in the hematopoietic system resulting from somatic mutations in driver genes are prevalent in elderly individuals who lack overt hematologic disorders. This condition is referred to as age-related clonal hematopoiesis (CH), and it is a newly recognized risk factor for cardiovascular disease. It is not known whether CH and hypertension in the elderly are causally related and, if so, what are the mechanistic features.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: A murine model of adoptive bone marrow transplantation was employed to examine the interplay between Tet2 (ten-eleven translocation methylcytosine dioxygenase 2) CH and hypertension. In this model, a subpressor dose of Ang II (angiotensin II) resulted in elevated systolic and diastolic blood pressure as early as 1 day after the challenge. These conditions led to the expansion of Tet2-deficient proinflammatory monocytes and bone marrow progenitor populations. Tet2-deficiency promoted renal CCL5 chemokine expression and macrophage infiltration into the kidney. Consistent with macrophage involvement, Tet2-deficiency in myeloid cells promoted hypertension when mice were treated with a subpressor dose of Ang II. The hematopoietic Tet2<sup>-</sup><sup>/-</sup> condition led to sodium retention, renal inflammasome activation, and elevated levels of IL (interleukin)-1β and IL-18. Analysis of the sodium transporters indicated NCC (Na<sup>+</sup>-Cl<sup>-</sup> cotransporter) and NKCC2 activation at residues Thr53 and Ser105, respectively. Administration of the NLRP3 inflammasome inhibitor MCC950 reversed the hypertensive state, sodium retention, and renal transporter activation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Tet2-mediated CH sensitizes mice to a hypertensive stimulus. Mechanistically, the expansion of hematopoietic Tet2-deficient cells promotes hypertension due to elevated renal immune cell infiltration and activation of the NLRP3 inflammasome, with consequences on sodium retention. These data indicate that carriers of TET2 CH could be at elevated risk for the development of hypertension and that immune modulators could be useful in treating hypertension in this patient population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39234670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39234670</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324492>10.1161/CIRCRESAHA.124.324492</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39234670</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ariel H Polizio</dc:creator>
<dc:creator>Lucila Marino</dc:creator>
<dc:creator>Kyung-Duk Min</dc:creator>
<dc:creator>Yoshimitsu Yura</dc:creator>
<dc:creator>Luca Rolauer</dc:creator>
<dc:creator>Jesse D Cochran</dc:creator>
<dc:creator>Megan A Evans</dc:creator>
<dc:creator>Eunbee Park</dc:creator>
<dc:creator>Heather Doviak</dc:creator>
<dc:creator>Emiri Miura-Yura</dc:creator>
<dc:creator>Miranda E Good</dc:creator>
<dc:creator>Abigail G Wolpe</dc:creator>
<dc:creator>Maria Grandoch</dc:creator>
<dc:creator>Brant Isakson</dc:creator>
<dc:creator>Kenneth Walsh</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Experimental TET2 Clonal Hematopoiesis Predisposes to Renal Hypertension Through an Inflammasome-Mediated Mechanism</dc:title>
<dc:identifier>pmid:39234670</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324492</dc:identifier>
</item>
<item>
<title>Exploring the Need for Precise MI Adjudication in Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39233110/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 26:S0735-1097(24)08277-9. doi: 10.1016/j.jacc.2024.08.046. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39233110/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39233110</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.046>10.1016/j.jacc.2024.08.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39233110</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael J Blaha</dc:creator>
<dc:creator>Andrew P DeFilippis</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Exploring the Need for Precise MI Adjudication in Clinical Trials</dc:title>
<dc:identifier>pmid:39233110</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.046</dc:identifier>
</item>
<item>
<title>Reply: Significance of B-type Natriuretic Peptide Level in Patients With Small Left Ventricle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232640/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e89. doi: 10.1016/j.jacc.2024.06.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232640/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232640</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.030>10.1016/j.jacc.2024.06.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232640</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mingxiao Li</dc:creator>
<dc:creator>Liu He</dc:creator>
<dc:creator>Lan Ren</dc:creator>
<dc:creator>Caihua Sang</dc:creator>
<dc:creator>Changsheng Ma</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Significance of B-type Natriuretic Peptide Level in Patients With Small Left Ventricle</dc:title>
<dc:identifier>pmid:39232640</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.030</dc:identifier>
</item>
<item>
<title>Significance of B-Type Natriuretic Peptide Level in Patients With Small Left Ventricle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232639/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e87. doi: 10.1016/j.jacc.2024.05.071.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232639/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232639</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.071>10.1016/j.jacc.2024.05.071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232639</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Tomoaki Murakami</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Significance of B-Type Natriuretic Peptide Level in Patients With Small Left Ventricle</dc:title>
<dc:identifier>pmid:39232639</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.071</dc:identifier>
</item>
<item>
<title>Reply: Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232638/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e85-e86. doi: 10.1016/j.jacc.2024.06.031.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232638/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232638</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.031>10.1016/j.jacc.2024.06.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232638</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ziwen Li</dc:creator>
<dc:creator>Ryan Wereski</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:creator>Dorien M Kimenai</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</dc:title>
<dc:identifier>pmid:39232638</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.031</dc:identifier>
</item>
<item>
<title>Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e83-e84. doi: 10.1016/j.jacc.2024.04.071.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232637</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.071>10.1016/j.jacc.2024.04.071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232637</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Amy G Huebschmann</dc:creator>
<dc:creator>Nanette K Wenger</dc:creator>
<dc:creator>C Noel Bairey Merz</dc:creator>
<dc:creator>Allan S Jaffe</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Stacy A Trent</dc:creator>
<dc:creator>Judith G Regensteiner</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</dc:title>
<dc:identifier>pmid:39232637</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.071</dc:identifier>
</item>
<item>
<title>Reply: The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232636/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e81. doi: 10.1016/j.jacc.2024.06.032.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232636/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232636</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.032>10.1016/j.jacc.2024.06.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232636</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yun Gi Kim</dc:creator>
<dc:creator>Hyoung Seok Lee</dc:creator>
<dc:creator>Hoseob Kim</dc:creator>
<dc:creator>Jong-Il Choi</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</dc:title>
<dc:identifier>pmid:39232636</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.032</dc:identifier>
</item>
<item>
<title>The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e79. doi: 10.1016/j.jacc.2024.03.434.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232635</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.434>10.1016/j.jacc.2024.03.434</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232635</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>James A Reiffel</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</dc:title>
<dc:identifier>pmid:39232635</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.434</dc:identifier>
</item>
<item>
<title>Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients with recent ACS on optimized statin therapy, baseline triglycerides was associated with cardiovascular risk. However, the reduction in triglycerides with alirocumab did not contribute to its clinical benefit. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):994-1006. doi: 10.1016/j.jacc.2024.06.035.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: It is unknown whether clinical benefit of proprotein convertase subtilisin/kexin type 9 inhibitors is associated with baseline or on-treatment triglyceride concentrations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to examine relations between triglyceride levels and the effect of alirocumab vs placebo on cardiovascular outcomes using prespecified and post hoc analyses of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with recent acute coronary syndrome (ACS) (n = 18,924) and elevated atherogenic lipoproteins despite optimized statin therapy were randomized to alirocumab 75 to 150 mg or matching placebo every 2 weeks subcutaneously. Major adverse cardiovascular events (MACE) were examined in relation to continuous or dichotomous triglyceride concentrations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Median baseline triglyceride concentration was 129 mg/dL. In both treatment groups, a 10-mg/dL higher baseline concentration was associated with an adjusted MACE HR of 1.008 (95% CI: 1.003-1.013; P &lt; 0.005). Baseline triglycerides ≥150 vs &lt;150 mg/dL were associated with a HR of 1.184 (95% CI: 1.080-1.297; P &lt; 0.005). Versus placebo, alirocumab reduced low-density lipoprotein cholesterol from baseline (average, 54.7%) and reduced MACE (HR: 0.85; 95% CI: 0.78-0.93). At month 4, triglyceride levels were reduced from baseline by median 17.7 mg/dL (P &lt; 0.001) and 0.9 mg/dL (P = NS) with alirocumab and placebo, respectively. A 10-mg/dL decline from baseline in triglycerides was associated with lower subsequent risk of MACE with placebo (HR: 0.988; 95% CI: 0.982-0.995; P &lt; 0.005) but not with alirocumab (HR: 0.999; 95% CI: 0.987-1.010; P = 0.82).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with recent ACS on optimized statin therapy, baseline triglycerides was associated with cardiovascular risk. However, the reduction in triglycerides with alirocumab did not contribute to its clinical benefit. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232634</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.035>10.1016/j.jacc.2024.06.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232634</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Doron Zahger</dc:creator>
<dc:creator>Gregory G Schwartz</dc:creator>
<dc:creator>Weiming Du</dc:creator>
<dc:creator>Michael Szarek</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Vera A Bittner</dc:creator>
<dc:creator>Andrzej J Budaj</dc:creator>
<dc:creator>Rafael Diaz</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>J Wouter Jukema</dc:creator>
<dc:creator>Robert G Kiss</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>Patrick M Moriarty</dc:creator>
<dc:creator>Michel Scemama</dc:creator>
<dc:creator>Garen Manvelian</dc:creator>
<dc:creator>Robert Pordy</dc:creator>
<dc:creator>Harvey D White</dc:creator>
<dc:creator>Andreas M Zeiher</dc:creator>
<dc:creator>Sergio Fazio</dc:creator>
<dc:creator>Gregory P Geba</dc:creator>
<dc:creator>Ph Gabriel Steg</dc:creator>
<dc:creator>ODYSSEY OUTCOMES Investigators</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome</dc:title>
<dc:identifier>pmid:39232634</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.035</dc:identifier>
</item>
<item>
<title>Rethinking Cholesterol Screening and Management in Young Adults: From Lost Opportunity to Prevention Win</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232633/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):974-977. doi: 10.1016/j.jacc.2024.06.029.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232633/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232633</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.029>10.1016/j.jacc.2024.06.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232633</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yiyi Zhang</dc:creator>
<dc:creator>Mark J Pletcher</dc:creator>
<dc:creator>Andrew E Moran</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Rethinking Cholesterol Screening and Management in Young Adults: From Lost Opportunity to Prevention Win</dc:title>
<dc:identifier>pmid:39232633</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.029</dc:identifier>
</item>
<item>
<title>Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Single measures of non-HDL-C and LDL-C obtained between ages 18 and 30 years are highly predictive of cumulative exposure before age 40 years, which in turn strongly predicts later-life ASCVD events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):961-973. doi: 10.1016/j.jacc.2024.05.070.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The ability of a 1-time measurement of non-high-density lipoprotein cholesterol (non-HDL-C) or low-density lipoprotein cholesterol (LDL-C) to predict the cumulative exposure to these lipids during early adulthood (age 18-40 years) and the associated atherosclerotic cardiovascular disease (ASCVD) risk after age 40 years is not clear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The objectives of this study were to evaluate whether a 1-time measurement of non-HDL-C or LDL-C in a young adult can predict cumulative exposure to these lipids during early adulthood, and to quantify the association between cumulative exposure to non-HDL-C or LDL-C during early adulthood and the risk of ASCVD after age 40 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We included CARDIA (Coronary Artery Risk Development in Young Adults Study) participants who were free of cardiovascular disease before age 40 years, were not taking lipid-lowering medications, and had ≥3 measurements of LDL-C and non-HDL-C before age 40 years. First, we assessed the ability of a 1-time measurement of LDL-C or non-HDL-C obtained between age 18 and 30 years to predict the quartile of cumulative lipid exposure from ages 18 to 40 years. Second, we assessed the associations between quartiles of cumulative lipid exposure from ages 18 to 40 years with ASCVD events (fatal and nonfatal myocardial infarction and stroke) after age 40 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 4,104 CARDIA participants who had multiple lipid measurements before and after age 30 years, 3,995 participants met our inclusion criteria and were in the final analysis set. A 1-time measure of non-HDL-C and LDL-C had excellent discrimination for predicting membership in the top or bottom quartiles of cumulative exposure (AUC: 0.93 for the 4 models). The absolute values of non-HDL-C and LDL-C that predicted membership in the top quartiles with the highest simultaneous sensitivity and specificity (highest Youden's Index) were >;135 mg/dL for non-HDL-C and >;118 mg/dL for LDL-C; the values that predicted membership in the bottom quartiles were &lt;107 mg/dL for non-HDL-C and &lt;96 mg/dL for LDL-C. Individuals in the top quartile of non-HDL-C and LDL-C exposure had demographic-adjusted HRs of 4.6 (95% CI: 2.84-7.29) and 4.0 (95% CI: 2.50-6.33) for ASCVD events after age 40 years, respectively, when compared with each bottom quartile.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Single measures of non-HDL-C and LDL-C obtained between ages 18 and 30 years are highly predictive of cumulative exposure before age 40 years, which in turn strongly predicts later-life ASCVD events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232632</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.070>10.1016/j.jacc.2024.05.070</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232632</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>John T Wilkins</dc:creator>
<dc:creator>Hongyan Ning</dc:creator>
<dc:creator>Norrina B Allen</dc:creator>
<dc:creator>Alexander Zheutlin</dc:creator>
<dc:creator>Nilay S Shah</dc:creator>
<dc:creator>Matthew J Feinstein</dc:creator>
<dc:creator>Amanda M Perak</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Ankeet S Bhatt</dc:creator>
<dc:creator>Ravi Shah</dc:creator>
<dc:creator>Venkatesh Murthy</dc:creator>
<dc:creator>Allan Sniderman</dc:creator>
<dc:creator>Donald M Lloyd-Jones</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood</dc:title>
<dc:identifier>pmid:39232632</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.070</dc:identifier>
</item>
<item>
<title>Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):1041-1045. doi: 10.1016/j.jacc.2024.06.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232631</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.025>10.1016/j.jacc.2024.06.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232631</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Milind Y Desai</dc:creator>
<dc:creator>Anjali Owens</dc:creator>
<dc:creator>Kathy Wolski</dc:creator>
<dc:creator>Jeffrey B Geske</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Andrew Wang</dc:creator>
<dc:creator>Mark Sherrid</dc:creator>
<dc:creator>Paul C Cremer</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Albree Tower-Rader</dc:creator>
<dc:creator>David Fermin</dc:creator>
<dc:creator>Srihari S Naidu</dc:creator>
<dc:creator>Nicholas G Smedira</dc:creator>
<dc:creator>Hartzell Schaff</dc:creator>
<dc:creator>Ellen McErlean</dc:creator>
<dc:creator>Christina Sewell</dc:creator>
<dc:creator>Yue Zhong</dc:creator>
<dc:creator>Kathleen W Wyrwich</dc:creator>
<dc:creator>Kathy L Lampl</dc:creator>
<dc:creator>Amy J Sehnert</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>VALOR-HCM Investigators</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial</dc:title>
<dc:identifier>pmid:39232631</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.025</dc:identifier>
</item>
<item>
<title>Competing Risks in Clinical Trials: Do They Matter and How Should We Account for Them?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232630/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>During patient follow-up in a randomized trial, some deaths may occur. Where death (or noncardiovascular death) is not part of an outcome of interest it is termed a competing risk. Conventional analyses (eg, Cox proportional hazards model) handle death similarly to other censored follow-up. Patients still alive are unrealistically assumed to be representative of those who died. The Fine and Gray model has been used to handle competing risks, but is often used inappropriately and can be...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):1025-1037. doi: 10.1016/j.jacc.2024.06.023.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">During patient follow-up in a randomized trial, some deaths may occur. Where death (or noncardiovascular death) is not part of an outcome of interest it is termed a competing risk. Conventional analyses (eg, Cox proportional hazards model) handle death similarly to other censored follow-up. Patients still alive are unrealistically assumed to be representative of those who died. The Fine and Gray model has been used to handle competing risks, but is often used inappropriately and can be misleading. We propose an alternative multiple imputation approach that plausibly accounts for the fact that patients who die tend also to be at high risk for the (unobserved) outcome of interest. This provides a logical framework for exploring the impact of a competing risk, recognizing that there is no unique solution. We illustrate these issues in 3 cardiovascular trials and in simulation studies. We conclude with practical recommendations for handling competing risks in future trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232630/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232630</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.023>10.1016/j.jacc.2024.06.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232630</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>John Gregson</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Cordula Zeller</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Competing Risks in Clinical Trials: Do They Matter and How Should We Account for Them?</dc:title>
<dc:identifier>pmid:39232630</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.023</dc:identifier>
</item>
<item>
<title>Pediatric Sedation Gets a Wake-Up Call</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232629/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):1022-1024. doi: 10.1016/j.jacc.2024.06.034.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232629/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232629</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.034>10.1016/j.jacc.2024.06.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232629</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>John N Kheir</dc:creator>
<dc:creator>Taylor M Smith</dc:creator>
<dc:creator>James A DiNardo</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Pediatric Sedation Gets a Wake-Up Call</dc:title>
<dc:identifier>pmid:39232629</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.034</dc:identifier>
</item>
<item>
<title>Association of Postnatal Opioid Exposure and 2-Year Neurodevelopmental Outcomes in Infants Undergoing Cardiac Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232628/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Greater postnatal exposure to opioids was associated with worse neurodevelopmental outcomes across cognitive, language, and motor domains, independent of other less modifiable factors. This finding should motivate research and efforts to explore reduction in opioid exposure while preserving quality cardiac intensive care.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):1010-1021. doi: 10.1016/j.jacc.2024.06.033.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Opioids are commonly used to provide analgesia during and after congenital heart surgery. The effects of exposure to opioids on neurodevelopment in neonates and infants are not well understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate the associations between cumulative opioid exposure (measured in morphine mg equivalent) over the first year of life and 2-year neurodevelopmental outcomes (Bayley Scales of Infant and Toddler Development-Third/Fourth Edition [Bayley-III/IV] cognitive, language, and motor scores).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A single-center retrospective cohort study of infants undergoing congenital heart surgery was performed. Adjustment for measurable confounders was performed through multivariable linear regression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 526 subjects were studied, of whom 32% underwent Society for Thoracic Surgeons-European Association for Cardio-Thoracic Surgery category 4 or 5 operations. In unadjusted analyses, higher total exposure to opioids was associated with worse scores across all 3 Bayley-III/IV domain scores (all P &lt; 0.05). After adjustment for measured confounders, greater opioid exposure was associated with lower Bayley-III/IV scores (cognitive: β = -1.0 per log-transformed morphine mg equivalents, P = 0.04; language: β = -1.2, P = 0.04; and motor: β = -1.1, P = 0.02). Total hospital length of stay, prematurity, genetic syndromes, and worse neighborhood socioeconomic status (represented either by Social Vulnerability Index or Childhood Opportunity Index) were all associated with worse Bayley-III/IV scores across all domains (all P &lt; 0.05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Greater postnatal exposure to opioids was associated with worse neurodevelopmental outcomes across cognitive, language, and motor domains, independent of other less modifiable factors. This finding should motivate research and efforts to explore reduction in opioid exposure while preserving quality cardiac intensive care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232628/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232628</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.033>10.1016/j.jacc.2024.06.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232628</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael L O'Byrne</dc:creator>
<dc:creator>Keith Baxelbaum</dc:creator>
<dc:creator>Vicky Tam</dc:creator>
<dc:creator>Heather Griffis</dc:creator>
<dc:creator>Maryjane L Pennington</dc:creator>
<dc:creator>Alyssa Hagerty</dc:creator>
<dc:creator>Maryam Y Naim</dc:creator>
<dc:creator>Susan C Nicolson</dc:creator>
<dc:creator>Amanda J Shillingford</dc:creator>
<dc:creator>Tori N Sutherland</dc:creator>
<dc:creator>Lyla E Hampton</dc:creator>
<dc:creator>Nebiat G Gebregiorgis</dc:creator>
<dc:creator>Thuyvi Nguyen</dc:creator>
<dc:creator>Elizabeth Ramos</dc:creator>
<dc:creator>Joseph W Rossano</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Postnatal Opioid Exposure and 2-Year Neurodevelopmental Outcomes in Infants Undergoing Cardiac Surgery</dc:title>
<dc:identifier>pmid:39232628</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.033</dc:identifier>
</item>
<item>
<title>Triglycerides and Cardiovascular Risk: Getting to the Heart of the Matter</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232627/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):1007-1009. doi: 10.1016/j.jacc.2024.07.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232627/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39232627</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.027>10.1016/j.jacc.2024.07.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232627</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter P Toth</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Triglycerides and Cardiovascular Risk: Getting to the Heart of the Matter</dc:title>
<dc:identifier>pmid:39232627</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.027</dc:identifier>
</item>
<item>
<title>Sudden Hemodynamic Deterioration of a 75-Year-Old Woman With Progressive Jaw Pain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230916/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905161100&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 4. doi: 10.1001/jamacardio.2024.2695. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230916/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905161100&v=2.18.0.post9+e462414">39230916</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2695>10.1001/jamacardio.2024.2695</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230916</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sven L Van Laer</dc:creator>
<dc:creator>Pieterjan Van Rijckeghem</dc:creator>
<dc:creator>Vincent F M Segers</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sudden Hemodynamic Deterioration of a 75-Year-Old Woman With Progressive Jaw Pain</dc:title>
<dc:identifier>pmid:39230916</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2695</dc:identifier>
</item>





























</channel>
</rss>